Abstract
Alisertib inhibits aurora A kinase (AAK), a serine/threonine kinases required for mitotic entry, chromosome alignment, centrosome maturation and separation, and spindle assembly checkpoint.[1][1] As a single agent, alisertib can produce an overall response rate (ORR) of 27% in patients with relapsed
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
